DIATHEVA - Biomanufacturing of innovative diagnostics and reagents

Magazine / Items filtered by date: July 2015

DIATHEVA - Biomanufacturing of innovative diagnostics and reagents - Items filtered by date: July 2015

Agenus Acquires from Diatheva Novel Antibodies to Immuno-oncology Target CEACAM1

Target Expressed on Lymphocytes and Tumors Offers Unique Advantages for Unlocking the Immune Response to Fight Cancer

 

LEXINGTON, MA -- July 20, 2015 -- Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that it has acquired rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein expressed on T cell and NK cell lymphocytes from Diatheva s.r.l., an Italian biotech company controlled by SOL S.p.A.CEACAM1 is overexpressed in melanoma, bladder, lung, colon, pancreas, and gastric cancers and has been shown to modulate innate and adaptive immune suppression in pre-clinical studies. Antibodies targeting CEACAM1 are thought to have the potential to effectively treat cancer alone or in combination with other checkpoint modulator antibodies, including those in Agenus’ development pipeline.

Company certified
ISO9001
Certified N.
IT05/0576
crm@diatheva.com
Phone (+39) 0721 830605
Fax (+39) 0721 837154
 
website netcompany
P.IVA.01403060427

By navigating this website you provide your agreement to the use of cookies, which we use to improve your navigation experience and for statistical analysis. Read our Cookie Policy to learn more

Your Shopping Cart

 x 
Cart empty